<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00522886</url>
  </required_header>
  <id_info>
    <org_study_id>07-03-009</org_study_id>
    <nct_id>NCT00522886</nct_id>
  </id_info>
  <brief_title>Phase I Cetuximab and Concurrent Radio-chemotherapy</brief_title>
  <official_title>Determination of the Toxicity of Standard Dose Cetuximab Together With Concurrent Individualised, Isotoxic Accelerated Radiotherapy and Cisplatin-vinorelbine for Patients With Stage III Non-small Cell Lung Cancer: A Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Academisch Ziekenhuis Maastricht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the MTD toxicity of standard dose cetuximab together with concurrent
      individualized, isotoxic accelerated radiotherapy and cisplatin-vinorelbine
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase I trial with escalating doses of vinorelbine and standard doses of radiotherapy,
      cisplatin and cetuximab.

      Eligible patients receive 2 cycles of carboplatin (AUC 5) day 1 and gemcitabine (1250 mg/m2)
      days 1,8. One cycle duration is 21 days.

      Patients without progressive disease (PD) according to the RECIST criteria (appendix 1) will
      be entered in the phase I dose-escalation part of the study. Chest radiation is given
      concurrently with cetuximab, cisplatin and vinorelbine. The latter drug will be escalated in
      three steps until dose-limiting toxicity occurs.

      On day 43, i.e. 14 days after the last gemcitabine delivery, radiotherapy is started.

      Radiotherapy: In all patients in every dose-step, the radiation will be given as follows:
      first 3 weeks: 1.5 Gy BID to a dose of 45 Gy in 30 fractions, then 2 Gy QD to a mean lung
      dose (MLD, this is related to radiation-induced lung damage) of 19 Gy. Maximum dose: 69 Gy
      given in 5.5 weeks. Maximum dose to the spinal cord: 50 Gy.

      Cetuximab: All patients will receive a starting dose 400 mg/ m2 7 days before the beginning
      of radiotherapy (i.e. day 36), thereafter a weekly dose 250 mg/ m2 during the course of
      radiotherapy for 5 consecutive weeks. Cetuximab will be delivered at the same days as
      chemotherapy.

      Cisplatin: In all patients in every dose-step, cisplatin will be given as follows: Step 1, 2
      and 3: 50 mg/ m2 days 43, 50; 40 mg/m2 day 64.

      Vinorelbine will be escalated in three steps:

      Step 1: 10 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 2: 20 mg/ m2 days 43, 50; 8 mg/m2
      days 66 and 73. Step 3: 20 mg/ m2 days 43, 50; 15 mg/m2 days 66 and 73.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) 3 months after the ende of chemo-radiation</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>During and after chemo-radiation: (CTC 3.0) Dysphagia, Cough, Dyspnea, Skin rash, Myelitis, Neuropathy, Neutrophiles, Platelets, Hemoglobin, Diarrhea, Renal failure, Liver dysfunction, Tumour response 3 m. after end chemo-radiation and Survival</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Eligible patients will be given 2 cycles(of 21 days) of carboplatin (AUC 5) day 1 and gemcitabine (1250 mg/m2) days 1,8. Patients without progressive disease will be entered in the phase I dose-escalation part of the study. Chest radiation will be given concurrently with cetuximab, cisplatin and vinorelbine, which will be escalated in 3 steps until dose-limiting toxicity occurs.
14 days after the last gemcitabine (=day 43), radiotherapy is started : First 3 weeks: 1.5 Gy BID to a dose of 45 Gy in 30 fractions, then 2 Gy QD to a mean lung dose of 19 Gy. Cetuximab: 400 mg/m2 7 days before radiotherapy (= day 36) and during the course of radiotherapy a weekly dose 250 mg/m2. Cetuximab will be delivered at the same days as chemotherapy.
Cisplatin(all steps): 50 mg/m2 days 43, 50; 40 mg/m2 day 64.
Vinorelbine:
Step 1: 10 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 2: 20 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 3: 20 mg/ m2 days 43, 50; 15 mg/m2 days 66 and 73.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed non-small cell lung cancer

          -  Inoperable stage III (UICC 2002; sixth edition) (no pleural effusion)

          -  WHO performance status 0 or 1

          -  Less than 10% weight loss in the last 6 months

          -  Lung function: FEV1 at least 50% and DLCO at least 50% of the predicted value

          -  No recent severe cardiac disease

          -  Adequate bone marrow function

          -  Adequate renal function

          -  Adequate hepatic function

          -  Life expectancy more than 6 months

          -  Measurable cancer

          -  Willing and able to comply with study prescriptions

          -  18 years or older

          -  Not pregnant or breast feeding

          -  Written informed consent

          -  No previous radiotherapy to the chest

        Exclusion Criteria:

          -  Not non-small cell lung cancer histology

          -  Mixed pathology

          -  History of prior chest radiotherapy

          -  Recent (&lt;3 months) myocardial infarction

          -  Uncontrolled infectious disease

          -  Less than 18 years old

          -  Inadequate pulmonary function

          -  Other active malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk De Ruysscher, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastro Clinic, The Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne-Marie Dingemans, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>academisch ziekenhuis Maastricht, azM</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht Radiation Oncology, MAASTRO clinic</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2007</study_first_submitted>
  <study_first_submitted_qc>August 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2007</study_first_posted>
  <last_update_submitted>July 18, 2011</last_update_submitted>
  <last_update_submitted_qc>July 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. Dirk De Ruysscher</name_title>
    <organization>Maastricht Radiation Oncology</organization>
  </responsible_party>
  <keyword>cetuximab</keyword>
  <keyword>concurrent</keyword>
  <keyword>iso-toxic</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

